Our innovative anti-inflammatory technology
Based upon on our Chief Scientific Officer Prof Len Lichtenberger’s experience on how phospholipids, and specifically phosphatidylcholine (PC), can protect the gastrointestinal (GI) mucosa from the injurious action of aspirin and related NSAIDs, a novel patent-protected method has been developed to synthesize purified PC-associated aspirin/NSAIDs.
These PC-associated drugs have improved GI safety and full therapeutic (analgesic and anti-inflammatory) activity. Due to the close “chemical relationship” between aspirin and our drug (JD-004) without any of the unwanted bleeding risks with aspirin, we were excited to find that we could use our novel method to synthesize JD-005, which can be readily suspended into saline and other biological-compatible buffers as a uni-lammelar liposomal suspension.
It is our aim to use this JD-005 product either as a liposomal suspension or freeze-dried powder to treat TBI, burn-injury and post-surgical pain.
-
JD-004 Based Formulation
We’re excited to unveil our latest achievement: a groundbreaking approach centered around the active pharmaceutical ingredient of JD-004 (i.e., salicylate). Leveraging our exclusive liposomal formulation technology, we’ve crafted multiple novel formulations.
-
Multiple formulations
J & D Pharmaceuticals is developing multiple formulations of JD-005:
- Parenteral (intravenous, intramuscular, and subcutaneous)
- Oral (suspension, tablet, capsule, gelcap, and caplet)
- Topical (lotion, cream, and powder)
-
Targeting Serious Military-Related Conditions
From traumatic brain injury to burns and post-op pain, our innovative formulations hold promise across a spectrum of serious military-related conditions. By harnessing the potential of JD-004, we’re poised to make a meaningful impact on patient care and treatment outcomes.
-
Pioneering Safety and Efficacy
Our commitment to patient well-being drives every aspect of our innovation. Through the preassociation technique, we’re not just delivering medication – we’re delivering peace of mind, knowing that safety remains paramount in every dose.
Frequently Asked Questions
How is your product different from aspirin?
Aspirin has the acetyl group as part of its chemical name, “acetylsalicylic acid”. It is this acetyl group that is responsible for the serious bleeding risks associated with aspirin. Our product has no such acetyl group which explains the lack of bleeding associated with JD-004.
Why has salicylsalicylic been on the market for over a century yet not FDA approved?
Our product is undergoing the proper FDA testing requirements to receive a new drug approval (NDA). All current products that contain JD-004 in America are marketed, but not approved by, the FDA.
Is salicylsalicylic safe to take in patients with heart disease?
In a long term 30 month study testing JD-004 in patients with established coronary artery disease, there was no. higher rate of any serious adverse reactions (SAE’s) in those patients treated with JD-004 compared to placebo tablets.